BofA raised the firm’s price target on Abbott (ABT) to $150 from $133 and keeps a Buy rating on the shares. Given the current premium, the firm thinks “there’s probably not a lot of room left” on the multiple, arguing that upside from here is dependent on double digit EPS growth and M&A. The firm moved its valuation year from 2025 EPS to 2026 EPS, the analyst noted.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT: